Overview
The GOG-0218 and ICON7 clinical trials demonstrated that adding bevacizumab to first-line (1L) chemotherapy improved progression-free survival compared to chemotherapy only in patients with stage III/IV epithelial ovarian cancer (EOC), however, no overall survival benefit was observed in the overall trial study populations. Additional analyses of the trial data indicated that adding bevacizumab to 1L chemotherapy was associated with a greater benefit among patients with high-risk prognostic factors. Given changes in the treatment landscape over the past decade, updated real-world data are needed to identify which patients benefit most from bevacizumab. This study examines the demographic and clinical profiles of EOC patients treated with 1L chemotherapy with or without bevacizumab and evaluates the potential benefit of adding bevacizumab to 1L chemotherapy on real-world outcomes in patients with or without high-risk clinical factors.
Researchers found that real-world results support clinical trial data, suggesting that the benefit of adding bevacizumab to a 1L chemotherapy regimen may largely be limited to patients with high-risk clinical factors, defined as stage IV disease, stage III disease with visible residual disease, or stage III disease with no evidence of surgery.
Why this matters
This real-world study is essential as it validates findings from phase III trials, indicating that the advantages of adding bevacizumab to 1L chemotherapy may be limited to patients with high-risk clinical factors. By leveraging real-world evidence, this research provides valuable insights that can assist clinicians in tailoring treatment strategies to individual patient needs based on risk status and other factors, thereby optimizing ovarian cancer management.